REFERENCES

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016). Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation. Immunity, 44(5), 989. https://doi.org/10.1016/j.immuni.2016.05.001

Baldanzi G. (2022). Immune Checkpoint Receptors Signaling in T Cells. International journal of molecular sciences, 23(7), 3529. https://doi.org/10.3390/ijms23073529

Balke-Want, H., Keerthi, V., Cadinanos-Garai, A., Fowler, C., Gkitsas, N., Brown, A. K., Tunuguntla, R., & Feldman, S. A. (2023). Non-viral chimeric antigen receptor (CAR) T cells going viral. Immuno-Oncology and Technology, 18. https://doi.org/10.1016/j.iotech.2023.100375

Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016). Toxicity and management in CAR T-cell therapy. *Molecular Therapy-Oncolytics, 3*. https://doi.org/10.1038/mto.2016.11

Bozso, S. J., Kang, J. J. H., & Nagendran, J. (2020). The role of competing mechanisms on Lck regulation. Immunologic research, 68(5), 289–295. https://doi.org/10.1007/s12026-020-09148-2

Chang, V. T., Fernandes, R. A., Ganzinger, K. A., Lee, S. F., Siebold, C., McColl, J., Jönsson, P., Palayret, M., Harlos, K., Coles, C. H., Jones, E. Y., Lui, Y., Huang, E., Gilbert, R. J., Klenerman, D., Aricescu, A. R., & Davis, S. J. (2016). Initiation of T cell signaling by CD45 segregation at 'close contacts'. Nature Immunology, 17(5), 574-582. https://doi.org/10.1038/ni.3392

Chen, B. J., Dashnamoorthy, R., Galera, P., Makarenko, V., Chang, H., Ghosh, S., & Evens, A. M. (2019). The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget, 10(21), 2030-2040. https://doi.org/10.18632/oncotarget.26771

Chen, N., Morello, A., Tano, Z., & Adusumilli, P. S. (2017). CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology, 6(2). https://doi.org/10.1080/2162402X.2016.1273302

Clark, R. A. (2015). Resident memory T cells in human health and disease. *Science translational medicine, 7*(269), 269rv1-269rv1. https://doi.org/10.1126/scitranslmed.3010641

Cordoba, P., Choudhuri, K., Zhang, H., Bridge, M., Basat, A. B., & Dustin, M. L. (2013). The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor. Blood, 121(21), 4295-4302. https://doi.org/10.1182/blood-2012-07-442251

Courtney, A. H., Shvets, A. A., Lu, W., Griffante, G., Mollenauer, M., Horkova, V., Lo, L., Yu, S., Stepanek, O., Chakraborty, A. K., & Weiss, A. (2019). CD45 functions as a signaling gatekeeper in T cells. Science Signaling, 12(604). https://doi.org/10.1126/scisignal.aaw8151

Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., ... & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. *Nature reviews Clinical oncology, 18*(6), 345-362. https://doi.org/10.1038/s41571-021-00473-5

Ehrke-Schulz, E., Schiwon, M., Leitner, T., Dávid, S., Bergmann, T., Liu, J., & Ehrhardt, A. (2017). CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes. Scientific reports, 7(1), 17113. https://doi.org/10.1038/s41598-017-17180-w

Elmas, E., Saljoughian, N., Pereira, S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022). CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.834002

Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017). Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European journal of cancer (Oxford, England : 1990), 81, 116–129. https://doi.org/10.1016/j.ejca.2017.01.035

Feucht, J., Sun, J., Eyquem, J., Ho, Y., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2018). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine, 25(1), 82-88. https://doi.org/10.1038/s41591-018-0290-5

Gajewski, T. F., Schreiber, H., & Fu, Y. X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nature immunology, 14(10), 1014–1022. https://doi.org/10.1038/ni.2703

Guerriero, J. L. (2019). Macrophages: their untold story in T cell activation and function. International *Review of Cell and Molecular Biology, 342*, 73-93. https://doi.org/10.1016/bs.ircmb.2018.07.001

Graham, D. B., & Root, D. E. (2015). Resources for the design of CRISPR gene editing experiments. Genome biology, 16, 260. https://doi.org/10.1186/s13059-015-0823-x

Hartmann, J., Bondanza, A., & Buchholz, C. J. (2017). Clinical development of CAR T cells—Challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine, 9(9), 1183-1197. https://doi.org/10.15252/emmm.201607485

Hryhorowicz, M., Lipiński, D., Zeyland, J., & Słomski, R. (2017). CRISPR/Cas9 Immune System as a Tool for Genome Engineering. Archivum immunologiae et therapiae experimentalis, 65(3), 233–240. https://doi.org/10.1007/s00005-016-0427-5

Ishibashi, A., Saga, K., Hisatomi, Y., Li, Y., Kaneda, Y., & Nimura, K. (2020). A simple method using CRISPR-Cas9 to knock-out genes in murine cancerous cell lines. Scientific Reports, 10(1), 1-10. https://doi.org/10.1038/s41598-020-79303-0

Jayaraman, J., Mellody, M. P., Hou, A. J., Desai, R. P., Fung, A. W., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine, 58, 102931. https://doi.org/10.1016/j.ebiom.2020.102931

Jiang, F., & Doudna, J. A. (2017). CRISPR–Cas9 Structures and Mechanisms. https://doi.org/10.1146/annurev-biophys-062215-010822

Jung, Y., Wen, L., Altman, A., & Ley, K. (2021). CD45 pre-exclusion from the tips of T cell microvilli prior to antigen recognition. Nature Communications, 12(1), 1-16. https://doi.org/10.1038/s41467-021-23792-8

Kalinin, R. S., Ukrainskaya, V. M., Chumakov, S. P., Moysenovich, A. M., Tereshchuk, V. M., Volkov, D. V., Pershin, D. S., Maksimov, E. G., Zhang, H., Maschan, M. A., Rubtsov, Y. P., & Stepanov, A. V. (2021). Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. Frontiers in Molecular Biosciences, 8, 745286. https://doi.org/10.3389/fmolb.2021.745286

Kumar, B. V., Connors, T. J., & Farber, D. L. (2018). Human T cell development, localization, and function throughout life. *Immunity, 48(*2), 202-213. https://doi.org/10.1016/j.immuni.2018.01.007

Li, B., Chan, H. L., & Chen, P. (2019). Immune checkpoint inhibitors: basics and challenges. *Current medicinal chemistry, 26*(17), 3009-3025. https://doi.org/10.2174/0929867324666170804143706

Li, J., Zhou, W., Li, D., Huang, Y., Yang, X., Jiang, L., Hu, X., Yang, J., Fu, M., Zhang, M., Wang, F., Li, J., Zhang, Y., Yang, Y., Yan, F., Gao, H., & Wang, W. (2023). Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice. Cancer Letters, 568, 216287. https://doi.org/10.1016/j.canlet.2023.216287

Liu, L., Wang, A., Liu, X., Han, S., Sun, Y., Zhang, J., Guo, L., & Zhang, Y. (2022). Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer. Journal of translational medicine, 20(1), 280. https://doi.org/10.1186/s12967-022-03480-x

Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2017). CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell research, 27(1), 154–157. https://doi.org/10.1038/cr.2016.142

Ma, Y., Zhang, L., & Huang, X. (2014). Genome modification by CRISPR/Cas9. The FEBS journal, 281(23), 5186–5193. https://doi.org/10.1111/febs.13110

Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. *Clinical therapeutics, 37*(4), 764-782. https://doi.org/10.1016/j.clinthera.2015.02.018

Majzner, R. G., & Mackall, C. L. (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nature medicine, 25(9), 1341–1355. https://doi.org/10.1038/s41591-019-0564-6

Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., Izadi, S., Hassanzadeh, A., Shirafkan, N., Tahmasebi, S., & Khiavi, F. M. (2021). CAR T cells in solid tumors: challenges and opportunities. Stem cell research & therapy, 12(1), 81. https://doi.org/10.1186/s13287-020-02128-1

McGowan, E., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2019). PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine & Pharmacotherapy, 121, 109625. https://doi.org/10.1016/j.biopha.2019.109625

Miliotou, A. N., & Papadopoulou, L. C. (2018). CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Current pharmaceutical biotechnology, 19(1), 5–18. https://doi.org/10.2174/1389201019666180418095526

Mucida, D., Husain, M. M., Muroi, S., Van Wijk, F., Shinnakasu, R., Naoe, Y., ... & Cheroutre, H. (2013). Transcriptional reprogramming of mature CD4+ helper T cells generates distinct MHC class II–restricted cytotoxic T lymphocytes. *Nature immunology, 14*(3), 281-289. https://doi.org/10.1038/ni.2523

Mueller, S. N., & Mackay, L. K. (2016). Tissue-resident memory T cells: local specialists in immune defence. *Nature Reviews Immunology, 16*(2), 79-89. https://doi.org/10.1038/nri.2015.3

Pauken, K. E., Godec, J., Odorizzi, P. M., Brown, K. E., Yates, K. B., Ngiow, S. F., Burke, K. P., Maleri, S., Grande, S. M., Francisco, L. M., Ali, A., Imam, S., Freeman, G. J., Haining, W. N., Wherry, E. J., & Sharpe, A. H. (2020). The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. *Cell Reports, 31*(13), 107827. https://doi.org/10.1016/j.celrep.2020.107827

Pennock, N. D., White, J. T., Cross, E. W., Cheney, E. E., Tamburini, B. A., & Kedl, R. M. (2013). T cell responses: naive to memory and everything in between. *Advances in physiology education, 37*(4), 273-283. https://doi.org/10.1152/advan.00066.2013

Picardo, S. L., Doi, J., & Hansen, A. R. (2019). Structure and Optimization of Checkpoint Inhibitors. Cancers, 12(1). https://doi.org/10.3390/cancers12010038

Poltorak, M. P., Graef, P., Tschulik, C., Wagner, M., Cletiu, V., Dreher, S., Borjan, B., Fraessle, S. P., Effenberger, M., Turk, M., Busch, D. H., Plitzko, J., Kugler, D. G., Ragan, S., Schmidt, T., Stemberger, C., & Germeroth, L. (2020). Expamers: A new technology to control T cell activation. Scientific Reports, 10(1), 1-15. https://doi.org/10.1038/s41598-020-74595-8

Rezalotfi, A., Fritz, L., Förster, R., & Bošnjak, B. (2022). Challenges of CRISPR-Based Gene Editing in Primary T Cells. International Journal of Molecular Sciences, 23(3). https://doi.org/10.3390/ijms23031689

Rheinländer, A., Schraven, B., & Bommhardt, U. (2018). CD45 in human physiology and clinical medicine. Immunology Letters, 196, 22-32. https://doi.org/10.1016/j.imlet.2018.01.009

Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science. https://doi.org/aar4060

Rodrigo, S., Senasinghe, K. & Quazi, S. Molecular and therapeutic effect of CRISPR in treating cancer. Med Oncol 40, 81 (2023). https://doi.org/10.1007/s12032-022-01930-6

Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports, 7(1), 1-10. https://doi.org/10.1038/s41598-017-00462-8

Roche, P. A., & Furuta, K. (2015). The ins and outs of MHC class II-mediated antigen processing and presentation. *Nature Reviews Immunology, 15*(4), 203-216. https://doi.org/10.1038/nri3818

Ross, S. H., & Cantrell, D. A. (2018). Signaling and Function of Interleukin-2 in T Lymphocytes. Annual Review of Immunology, 36, 411. https://doi.org/10.1146/annurev-immunol-042617-053352

Schenkel, J. M., & Masopust, D. (2014). Tissue-resident memory T cells. *Immunity, 41*(6), 886-897. http://dx.doi.org/10.1016/j.immuni.2014.12.007

Schoutrop, E., Poiret, T., El-Serafi, I., Zhao, Y., He, R., Moter, A., Henriksson, J., Hassan, M., Magalhaes, I., & Mattsson, J. (2023). Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. Journal for immunotherapy of cancer, 11(2), e005691. https://doi.org/10.1136/jitc-2022-005691

Song, W., & Zhang, M. (2020). Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clinical Immunology, 214, 108382. https://doi.org/10.1016/j.clim.2020.108382

Srivastava, S., & Riddell, S. R. (2015). Engineering CAR-T Cells: Design Concepts. Trends in Immunology, 36(8), 494. https://doi.org/10.1016/j.it.2015.06.004

Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4), 1-11. https://doi.org/10.1038/s41408-021-00459-7

Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., Sha, H., Cheng, L., Meng, F., Zou, Z., Huang, X., & Liu, B. (2016). CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Scientific Reports, 6(1), 1-14. https://doi.org/10.1038/srep20070

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Tanaka, A., & Sakaguchi, S. (2017). Regulatory T cells in cancer immunotherapy. *Cell research, 27*(1), 109-118. https://doi.org/10.1038/cr.2016.151

Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018). Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. *Nature reviews Drug discovery,* (12), 854-856. https://doi.org/10.1038/nrd.2018.209

Volkov, D. V., Stepanova, V. M., Rubtsov, Y. P., Stepanov, A. V., & Gabibov, A. G. (2023). Protein Tyrosine Phosphatase CD45 As an Immunity Regulator and a Potential Effector of CAR-T therapy. Acta Naturae, 15(3), 17-26. https://doi.org/10.32607/actanaturae.25438

Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021). The PD-1 Interactome. Advanced Biology, 5(9), 2100758. https://doi.org/10.1002/adbi.202100758

Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang, X., Cheng, C., Shen, L., He, J., Ye, X., Cao, W., Wang, H., & Han, W. (2021). Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cellular & Molecular Immunology, 18(9), 2188-2198. https://doi.org/10.1038/s41423-021-00749-x

Weber, E. W., Maus, M. V., & Mackall, C. L. (2020). The Emerging Landscape of Immune Cell Therapies. Cell, 181(1), 46–62. https://doi.org/10.1016/j.cell.2020.03.001

Wei, Y., Fan, J., Shan, X., Yin, D., Wang, L., Ye, W., & Zhao, W. (2022). TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection. American Journal of Translational Research, 14(2), 942-954. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902551/

Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020). TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 20(3), 173-185. https://doi.org/10.1038/s41577-019-0224-6

Xiao, Q., Zhang, X., Tu, L., Cao, J., Hinrichs, C. S., & Su, X. (2022). Size-dependent activation of CAR-T cells. Science Immunology. https://doi.org/abl3995

Xu, J., Zhang, Q., Tian, K., Wang, H., Yin, H., & Zheng, J. (2018). Current status and future prospects of the strategy of combining CAR-T with PD-1 blockade for antitumor therapy (Review). Molecular medicine reports, 17(2), 2083–2088. https://doi.org/10.3892/mmr.2017.8129

Yang, Z., Kim, H. J., Villasboas, J. C., Chen, P., Price-Troska, T., Jalali, S., Wilson, M., Novak, A. J., & Ansell, S. M. (2017). Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. Oncotarget, 8(37), 61425-61439. https://doi.org/10.18632/oncotarget.18251

Yudovich, D., Bäckström, A., Schmiderer, L., Žemaitis, K., Subramaniam, A., & Larsson, J. (2020). Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells. Scientific Reports, 10(1), 1-11. https://doi.org/10.1038/s41598-020-79724-x

Zak, K. M., Grudnik, P., Magiera, K., Dömling, A., Dubin, G., & Holak, T. A. (2017). Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure (London, England : 1993), 25(8), 1163–1174. https://doi.org/10.1016/j.str.2017.06.011

Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019). CRISPR/Cas9 for cancer research and therapy. Seminars in Cancer Biology, 55, 106-119. https://doi.org/10.1016/j.semcancer.2018.04.001

Zhao, Z., Shi, L., Zhang, W., Han, J., Zhang, S., Fu, Z., & Cai, J. (2017). CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. Oncotarget, 9(4), 5208-5215. https://doi.org/10.18632/oncotarget.23730

Zolov, S. N., Rietberg, S. P., & Bonifant, C. L. (2018). Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy, 20(10), 1259–1266. https://doi.org/10.1016/j.jcyt.2018.07.005